MDX2004
Advanced Cancers
Phase 1Active (Trial began Oct 2025)
Key Facts
About Opko Health
OPKO Health is a unique, fully-integrated biopharmaceutical and diagnostics company founded in 2007. Its core strategy combines the steady, high-volume revenue of its BioReference Laboratories diagnostics business with targeted therapeutic R&D in multispecific antibodies and long-acting delivery technologies. Key achievements include the global commercialization of NGENLA™ (somatrogon) with Pfizer and the marketing of RAYALDEE® for secondary hyperparathyroidism, while its research subsidiary, ModeX Therapeutics, advances a novel pipeline with partners like Merck and Regeneron. This hybrid model aims to de-risk drug development while pursuing transformative medicines for complex diseases.
View full company profileTherapeutic Areas
Other Advanced Cancers Drugs
| Drug | Company | Phase |
|---|---|---|
| DC-6001 (DCBY02) | DynamiCure | Phase 1 |
| DC-6001 (DCSZ11) | DynamiCure | Phase 1 (Planned) |
| INA03 | Inatherys | Preclinical |
| IBI-110 | Innovent Biologics | Phase 2 |
| NXP900 | Nuvectis Pharma | Phase 1 |